
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc. has demonstrated strong financial momentum, highlighted by Integrity achieving sequential revenue growth and a projected over 100% increase in 2025 revenue compared to 2024. The company's international osteoarthritis (OA) pain revenue reflected a robust 21% growth year-over-year, indicating expanding market acceptance of its products outside the U.S. Additionally, the regenerative solutions segment experienced impressive growth of 41% in Q1, significantly propelled by the Integrity patch, showcasing a solid performance across its therapeutic offerings.
Bears say
Anika Therapeutics, Inc. has reported a decline in revenue, generating $27.8 million, which marks a 5.9% decrease compared to the previous year, excluding recent divestitures, highlighting persistent challenges in revenue generation. The company also faced disappointing gross margins of 56%, falling short of the estimated 58%, primarily due to ongoing production yield issues that have negatively impacted operational efficiency. Additionally, the international revenue from osteoarthritis pain management declined by 10% compared to the same quarter last year, further emphasizing the company's struggles in maintaining stable growth in an already challenging market environment.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares